da Silva, Vanessa Kappel
de Freitas, Betânia Souza
Garcia, Rebeca Carvalho Lacerda
Monteiro, Ricardo Tavares
Hallak, Jaime Eduardo
Zuardi, Antônio Waldo
Crippa, José Alexandre S.
Schröder, Nadja http://orcid.org/0000-0002-4227-5702
Article History
Received: 12 March 2018
Revised: 3 July 2018
Accepted: 24 July 2018
First Online: 3 September 2018
Conflict of interest
: A.W.Z., J.E.C.H. and J.A.C. are co-inventors (Mechoulam R, J.C., Guimarães F.S., A.Z., J.H., Breuer A.) of the patent “Fluorinated CBD compounds, compositions and uses thereof. Pub. No.: WO/2014/108899. International Application No.: PCT/IL2014/050023” Def. US no. Reg. 62193296; 29/07/2015; INPI on 19/08/2015 (BR1120150164927). The University of São Paulo has licensed the patent to Phytecs Pharm (USP Resolution No. 15.1.130002.1.1). The University of São Paulo has an agreement with Prati-Donaduzzi (Toledo, Brazil) to “develop a pharmaceutical product containing synthetic cannabidiol and prove its safety and therapeutic efficacy in the treatment of epilepsy, schizophrenia, Parkinson’s disease, and anxiety disorders”. J.A.C. and J.E.C.H. received travel support from and are medical advisors of BSPG-Pharm. The other authors declare that they have no conflict of interest.